Relationship Between Sarcopenia and Minimal Hepatic Encephalopathy in Patients with Cirrhosis: a Prospective Observational Study

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2025 Feb 18

PMID 39962372

Authors

Wasit Wongtrakul

Wimolrak Bandidniyamanon

Phunchai Charatcharoenwitthaya

Affiliations

Soon will be listed here.

Abstract

Background: Sarcopenia, characterized by loss of muscle mass and function, has gained importance in the evaluation of cirrhotic patients. Evidence suggests its role in adverse clinical outcomes, including minimal hepatic encephalopathy (MHE). This study aimed to investigate the association between sarcopenia and MHE in patients with cirrhosis.

Methods: We prospectively enrolled outpatients with cirrhosis to assess sarcopenia using the 2019 criteria from the Asian Working Group for Sarcopenia. MHE was diagnosed through the Psychometric Hepatic Encephalopathy Score.

Results: Of the 210 cirrhotic patients (57.1% male, mean age 62.7 ± 9.6 years), 54 (25.7%) had sarcopenia, with 26 (12.3%) classified as severe. Thirty-seven patients (17.6%) were diagnosed with MHE. Sarcopenia prevalence was significantly higher in patients with MHE compared to those without MHE (45.9% vs. 21.4%). MHE was significantly associated with age, education level, Mini-Mental State Examination score, and a history of hepatic decompensation. No significant associations were found regarding gender, body mass index, comorbidities, sleep quality, and the etiology of cirrhosis. Multivariable logistic regression showed that MHE was significantly associated with age (adjusted odds ratio [aOR] 1.08, 95% CI 1.02-1.13), sarcopenia (aOR 3.29, 95% CI 1.44-7.50), history of overt hepatic encephalopathy (aOR 7.40, 95% CI 1.20-45.56), and variceal bleeding (aOR 3.13, 95% CI 1.38-7.10). Severe sarcopenia was also independently associated with MHE (aOR 3.64, 95% CI 1.32-10.05).

Conclusions: Sarcopenia is prevalent in cirrhotic patients and is associated with an increased risk of MHE. Our findings emphasize the importance of assessing sarcopenia to potentially mitigate MHE risk in managing patients with cirrhosis.

References

Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V . Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2012; 28(2):281-4. DOI: 10.1007/s11011-012-9365-z. View

Labenz C, Toenges G, Huber Y, Nagel M, Marquardt J, Schattenberg J . Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. Am J Gastroenterol. 2019; 114(5):764-770. DOI: 10.14309/ajg.0000000000000121. View

Bale A, Pai C, Shetty S, Balaraju G, Shetty A . Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. J Clin Exp Hepatol. 2018; 8(2):156-161. PMC: 5992259. DOI: 10.1016/j.jceh.2017.06.005. View

Dhaliwal A, Armstrong M . Sarcopenia in cirrhosis: A practical overview. Clin Med (Lond). 2020; 20(5):489-492. PMC: 7539699. DOI: 10.7861/clinmed.2020-0089. View

Campagna F, Montagnese S, Ridola L, Senzolo M, Schiff S, De Rui M . The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017; 66(1):198-208. DOI: 10.1002/hep.29146. View

Thanapirom K, Wongwandee M, Suksawatamnuay S, Thaimai P, Siripon N, Makhasen W . Psychometric Hepatic Encephalopathy Score for the Diagnosis of Minimal Hepatic Encephalopathy in Thai Cirrhotic Patients. J Clin Med. 2023; 12(2). PMC: 9864758. DOI: 10.3390/jcm12020519. View

Hanai T, Shiraki M, Watanabe S, Kochi T, Imai K, Suetsugu A . Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Res. 2017; 47(13):1359-1367. DOI: 10.1111/hepr.12873. View

Ruiz-Margain A, Xie J, Roman-Calleja B, Pauly M, White M, Chapa-Ibarguengoitia M . Phase Angle From Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis With or Without Ascites. Clin Gastroenterol Hepatol. 2020; 19(9):1941-1949.e2. DOI: 10.1016/j.cgh.2020.08.066. View

Espirito Santo Silva D, Waitzberg D, de Jesus R, de Oliveira L, Torrinhas R, Belarmino G . Phase angle as a marker for sarcopenia in cirrhosis. Clin Nutr ESPEN. 2019; 32:56-60. DOI: 10.1016/j.clnesp.2019.05.003. View

10.

Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S . Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2016; 15(6):934-936. DOI: 10.1016/j.cgh.2016.10.028. View

11.

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

12.

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

13.

Bajaj J, Lauridsen M, Tapper E, Duarte-Rojo A, Rahimi R, Tandon P . Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. Am J Gastroenterol. 2020; 115(7):989-1002. DOI: 10.14309/ajg.0000000000000603. View

14.

Allampati S, Duarte-Rojo A, Thacker L, Patidar K, White M, Klair J . Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study. Am J Gastroenterol. 2015; 111(1):78-86. DOI: 10.1038/ajg.2015.377. View

15.

Dhiman R, Kurmi R, Thumburu K, Venkataramarao S, Agarwal R, Duseja A . Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010; 55(8):2381-90. DOI: 10.1007/s10620-010-1249-7. View

16.

Saeki C, Takano K, Oikawa T, Aoki Y, Kanai T, Takakura K . Comparative assessment of sarcopenia using the JSH, AWGS, and EWGSOP2 criteria and the relationship between sarcopenia, osteoporosis, and osteosarcopenia in patients with liver cirrhosis. BMC Musculoskelet Disord. 2019; 20(1):615. PMC: 6933666. DOI: 10.1186/s12891-019-2983-4. View

17.

Rahimi R, Brown K, Flamm S, Brown Jr R . Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. Am J Med. 2021; 134(11):1330-1338. DOI: 10.1016/j.amjmed.2021.06.007. View

18.

Marrone G, Serra A, Miele L, Biolato M, Liguori A, Grieco A . Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties. World J Gastroenterol. 2023; 29(19):2905-2915. PMC: 10237095. DOI: 10.3748/wjg.v29.i19.2905. View

19.

Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T . Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013; 13(6):1549-56. DOI: 10.1111/ajt.12221. View

20.

Tantai X, Liu Y, Yeo Y, Praktiknjo M, Mauro E, Hamaguchi Y . Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2021; 76(3):588-599. DOI: 10.1016/j.jhep.2021.11.006. View